Literature DB >> 8593793

Characterization of inhibin/activin subunit, follistatin, and activin type II receptors in human ovarian cancer cell lines: a potential role in autocrine growth regulation.

N Di Simone1, W F Crowley, Q F Wang, P M Sluss, A L Schneyer.   

Abstract

Although ovarian cancer is the most common gynecological malignancy with a relatively poor 5-yr survival record, the mechanism(s) by which these tumors arise is not well understood. A role for inhibins and activins in regulating this transformation is suggested by the detection of circulating alpha or dimeric inhibin in some patients with ovarian cancer and by the alpha inhibin knockout mouse, in which development of gonadal tumors in 100% of homozygotes is associated with greatly elevated activin levels. To develop diagnostic tools with greater specificity for ovarian cancers, the present study was targeted at characterizing the biosynthetic capacity of the epithelial ovarian cancer cell lines from the American Type Culture Collection with respect to inhibin, activin, the related activin-binding protein follistatin (FS), and activin receptor type II. In addition, the functional capacity of this system was investigated by examining the ability of activin and FS to modulate cellular proliferation. All six cell lines contained abundant messenger RNA (mRNA) for activin receptor type II, but no inhibin alpha-subunit mRNA was detected in any cell line. Two cell lines contained mRNA for activin beta B-subunit (CaOV4 and SKOV3), one cell line contained beta A-subunit mRNA (SW626), and one cell line contained both (ES2); the latter also contained FS mRNA. FS mRNA was detected in another cell line (PA-1) that contained no detectable activin beta-subunit mRNA. Finally, one cell line (CaOV3) contained neither beta-subunit nor FS mRNA. Protein secretion was also examined. Consistent with the mRNA studies, the two cell lines containing FS mRNA secreted FS (PA-1 and ES2 cells), whereas three of the remaining lines secreted activin (A or B). In the cell line containing neither FS nor beta-subunit mRNA, no FS or activin could be detected. Finally, none of the cell lines secreted detectable immunoreactive inhibin. The effects of exogenous activin and FS on cellular proliferation were examined in these cell lines. No response was detected in the two cell lines that secreted FS (PA-1 and ES2). For the four cell lines not synthesizing FS, treatment with activin (1-100 ng/ml) resulted in an increase, whereas FS treatment (1-100 ng/ml) resulted in a decrease in cellular proliferation, as determined by [3H]thymidine incorporation. The response to activin correlated negatively with endogenous activin production, suggesting that autocrine activin production may be involved with cell proliferation. The differential expression and production of inhibin/activin subunits, activin receptors, and follistatin as well as the range of responses to exogenous activin among six ovarian epithelial cancer cell lines suggest that this family of hormones may be important in regulating cell proliferation in the ovary. Whether primary tumors have the same profile and the degree to which these results can be generalized to additional forms of ovarian cancer remain to be determined.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8593793     DOI: 10.1210/endo.137.2.8593793

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  10 in total

1.  Overexpression of activin A in stage IV colorectal cancer.

Authors:  S Wildi; J Kleeff; H Maruyama; C A Maurer; M W Büchler; M Korc
Journal:  Gut       Date:  2001-09       Impact factor: 23.059

Review 2.  Clinical and Therapeutic Implications of Follistatin in Solid Tumours.

Authors:  Lei Shi; Jeyna Resaul; Sioned Owen; Lin Ye; Wen G Jiang
Journal:  Cancer Genomics Proteomics       Date:  2016 11-12       Impact factor: 4.069

3.  The role of activin A and Akt/GSK signaling in ovarian tumor biology.

Authors:  Thuy-Vy Do; Lena A Kubba; Monica Antenos; Alfred W Rademaker; Charles D Sturgis; Teresa K Woodruff
Journal:  Endocrinology       Date:  2008-05-01       Impact factor: 4.736

4.  Identification of five candidate lung cancer biomarkers by proteomics analysis of conditioned media of four lung cancer cell lines.

Authors:  Chris Planque; Vathany Kulasingam; Chris R Smith; Karen Reckamp; Lee Goodglick; Eleftherios P Diamandis
Journal:  Mol Cell Proteomics       Date:  2009-09-23       Impact factor: 5.911

5.  Smad1-Smad5 ovarian conditional knockout mice develop a disease profile similar to the juvenile form of human granulosa cell tumors.

Authors:  Brooke S Middlebrook; Karen Eldin; Xiaohui Li; Sujatha Shivasankaran; Stephanie A Pangas
Journal:  Endocrinology       Date:  2009-10-09       Impact factor: 4.736

6.  BRCA1 regulates follistatin function in ovarian cancer and human ovarian surface epithelial cells.

Authors:  Tejaswita M Karve; Anju Preet; Rosie Sneed; Clara Salamanca; Xin Li; Jingwen Xu; Deepak Kumar; Eliot M Rosen; Tapas Saha
Journal:  PLoS One       Date:  2012-06-01       Impact factor: 3.240

7.  Genetic evidence that SMAD2 is not required for gonadal tumor development in inhibin-deficient mice.

Authors:  Saneal Rajanahally; Julio E Agno; Roopa L Nalam; Michael B Weinstein; Kate L Loveland; Martin M Matzuk; Qinglei Li
Journal:  Reprod Biol Endocrinol       Date:  2010-06-21       Impact factor: 5.211

8.  Presence of activin signal transduction in normal ovarian cells and epithelial ovarian carcinoma.

Authors:  I Ito; T Minegishi; J Fukuda; H Shinozaki; N Auersperg; P C Leung
Journal:  Br J Cancer       Date:  2000-04       Impact factor: 7.640

9.  Follistatin is a novel therapeutic target and biomarker in FLT3/ITD acute myeloid leukemia.

Authors:  Bai-Liang He; Ning Yang; Cheuk Him Man; Nelson Ka-Lam Ng; Chae-Yin Cher; Ho-Ching Leung; Leo Lai-Hok Kan; Bowie Yik-Ling Cheng; Stephen Sze-Yuen Lam; Michelle Lu-Lu Wang; Chun-Xiao Zhang; Hin Kwok; Grace Cheng; Rakesh Sharma; Alvin Chun-Hang Ma; Chi Wai Eric So; Yok-Lam Kwong; Anskar Yu-Hung Leung
Journal:  EMBO Mol Med       Date:  2020-03-05       Impact factor: 12.137

10.  Global gene expression in endometrium of high and low fertility heifers during the mid-luteal phase of the estrous cycle.

Authors:  Aideen P Killeen; Dermot G Morris; David A Kenny; Michael P Mullen; Michael G Diskin; Sinéad M Waters
Journal:  BMC Genomics       Date:  2014-03-26       Impact factor: 3.969

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.